Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tiziana Life Sciences PLC is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio is limited to 1 distinct examiner and a distinct art unit, indicating a very specific focus for the company's current patenting efforts. This concentration within the art unit suggests that the pending matter relates to a specialized area of biotechnology that does not overlap with other examination groups.
KIM, YUNSOO is the busiest examiner for this portfolio, overseeing the pending office action. With only the examiner involved in the pending action, the prosecution outcome is tied to the specific requirements of this individual. This centralized structure allows for a dedicated focus on the examiner's tendencies within the art unit. Legal counsel can optimize their strategy by analyzing the examiner's previous actions and the specific examination guidelines of the art unit to address the pending action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18317810 | NASAL FORMULATIONS OF FORALUMAB | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18317810 | NASAL FORMULATIONS OF FORALUMAB | KIM, YUNSOO | 1641 | §103§112DP | Final Rejection | — | Pending | May 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial